Interestingly, inactivation of B2M in cancer cells has been associated with downregulation of the MHC-I complex, abnormal immune surveillance that contributes to cancer development and attenuated responses to anti-PD-1/anti-PD-L1 immunotherapies [48], highlighting the potential for cancer EV cargoes to report on tumor immune status. This evidence concerns the gene CD274 and neoplasm.